StockPreacher.com Issues Technical Trading Overview for WuXi PharmaTech (Cayman) Inc.

DALLAS, Sept. 24, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring pharmaceutical company WuXi PharmaTech (Cayman) Inc. (NYSE:WX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on WuXi PharmaTech (Cayman) Inc. (NYSE:WX) should be of particular interest to other pharmaceutical companies: Covance Inc. (NYSE:CVD), Charles River Laboratories International Inc. (NYSE:CRL), ICON plc (Nasdaq:ICLR) and Parexel International Corp. (Nasdaq:PRXL).

The full report is available at: http://www.stockpreacher.com/n/WX

WuXi PharmaTech (Cayman) Inc. (WX), through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in the People's Republic of China and the United States. The Company provides laboratory services for pharmaceutical companies, which include discovery and medicinal chemistry, analytical chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology services, as well as drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion services. It also offers services in antibody generation, cell line development and biologics safety testing that support customers; biologics product development and commercialization; and medical device testing and development services.

In the report, the analyst notes:

"WX's financial performance in second quarter 2009 exceeded analyst expectations, both in revenues and profitability. Despite the difficult conditions, the Company succeeded to report strong revenues and significant improvement in profit margins. The Company is further expanding its operating capabilities and is planning to continue delivering strong revenue and earnings growth.

"In recent years, WX has built new capabilities in discovery biology, DMPK/ADME, formulation, toxicology, bioanalytical services, process research, analytical development services and other areas. These newer services have become increasingly significant revenue growth drivers as the Company offers an integrated platform of services. The Company has also expanded its services beyond development of small-molecule pharmaceuticals to include testing services for biologics and medical-device products."

To read the entire report visit: http://www.stockpreacher.com/n/WX

See what investors are saying about these stocks at: http://www.stockhideout.com/

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT:  StockPreacher.com
          Jeff Bishop
          (469)-252-3505
          press@beaconequity.com